A Phase 2 interventional study of Asedebart in Adrenal Hyperplasia, Congenital, sponsored by H. Lundbeck A/S. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by H. Lundbeck A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main goal of the trial is to study the long-term safety, how well people can handle the treatment, and how asedebart acts in the body and affects the body when used to treat classic congenital adrenal hyperplasia (CAH). The trial will include participants who have previously received asedebart in trial 19873A (NCT05669950).
101 studies on the registry are indexed under Adrenal Hyperplasia, Congenital; 28 are open to participants now.
This study's planned enrollment of 45 is above the median of 37 across 50 interventional studies indexed under Adrenal Hyperplasia, Congenital.
Browse Adrenal Hyperplasia, Congenital studies →H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
For participants with > 12 weeks since their last dose of asedebart: The participant is not adequately controlled on their current treatment and, at the Screening/Baseline Visit, has either:
Key Exclusion Criteria:
Other protocol-defined criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive asedebart per a prespecified dosing schedule.
Drug: Asedebart
Solution for injection/infusion
Also known as: Lu AG13909
Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Time frame: Up to 42 months
Serum Concentration of Asedebart
Time frame: Up to 42 months
Area Under the Asedebart Serum Concentration-time Curve in a Dosing Interval (AUC0-tau)
Time frame: Up to 73 days
Area Under the Asedebart Serum Concentration-time Curve From Start of Injection to 28 days Post-dose (AUC0-4W)
Time frame: Up to 73 days
Maximum Observed Serum Concentration of Asedebart (Cmax)
Time frame: Up to 73 days
Nominal Time Corresponding to the Occurrence of Cmax of Asedebart (Tmax)
Time frame: Up to 73 days
Minimum Observed Serum Concentration of Asedebart (Ctrough)
Time frame: Up to 73 days
Nominal Time Corresponding to the Occurrence of Ctrough (Ttrough)
Time frame: Up to 73 days
Number of Participants with Anti-drug Antibodies (ADAs) Following Dosing
Time frame: Up to 42 months
Relative Reduction from Baseline in Morning Concentrations of Androstenedione (A4) in Blood
Time frame: Baseline, Month 12, 24, and 36
Relative Reduction from Baseline in Morning Concentrations of 17-hydroxyprogesterone (17-OHP) in Blood
Time frame: Baseline, Month 12, 24, and 36
Relative Reduction from Baseline in Morning Concentrations of Glucocorticoid (GC) Daily Dose
Time frame: Baseline, Month 12, 24, and 36
No study locations are listed for this record.
Start is estimated for Oct 2026; primary completion for Jul 2031, 57 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Asedebart
Adrenal Hyperplasia, Congenital →